Xinghao Pharmaceutical’s Naloxone Hydrochloride Injection Expected to Win Bid in the Tenth National Centralized Procurement
December 16, 2024
Source: drugdu
40
On December 12, Xinghao Pharmaceutical announced that its subsidiary, Guangdong Xinghao Pharmaceutical Co., Ltd., participated in the bidding process organized by the Joint Procurement Office for the tenth batch of national centralized drug procurement. The company's product, Naloxone Hydrochloride Injection, is expected to win the bid in this centralized procurement, with an intended bid price of 1.37 yuan per vial.
It is reported that Naloxone Hydrochloride Injection is an opioid receptor antagonist used to counteract respiratory depression caused by opioid drugs in narcotic anesthesia and to promote patient awakening, as well as to rescue individuals from acute ethanol poisoning.
Xinghao Pharmaceutical stated that if the company subsequently signs a procurement contract and implements it, this will further expand the sales of related products, increase market share, enhance the company’s brand influence, and have a positive impact on the company's future operating performance.
https://finance.eastmoney.com/a/202412133267927671.html
By editor
Copyright©2024 Ddu. All rights reserved.
Read more on
- Yingtai Medical acquires Weiqiang Medical December 21, 2024
- 4 innovative medical devices approved for market launch December 21, 2024
- Once a month, potential “best-in-class” lipid-lowering drugs apply for listing December 21, 2024
- Notice! Xinma Pharmaceutical Recruitment and Procurement Involved in Bribery December 21, 2024
- New weight loss drug, the world’s first cAMP-biased GLP-1 agonist has been submitted for marketing December 21, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
